Assembly Bio files 8-K/A to correct filing tag on Q2 2026 results release
The amendment fixes a mislabeled item code from the original August 13 filing; no financial or pipeline content was changed.
SEC filing
Latest
3 stories
Friday, August 14
Thursday, August 13
Assembly Bio reports Q2 2026 results, expands ABI-6250 into cholestatic liver disease
Company closed a $115 million financing and disclosed Gilead's plan to advance GS-1179 into Phase 2 for genital herpes by year-end 2026.
SEC filing